IL-33 Protein (AA 112-270)
-
- Target See all IL-33 (IL33) Proteins
- IL-33 (IL33) (Interleukin 33 (IL33))
- Protein Type
- Recombinant
- Biological Activity
- Active
- Protein Characteristics
- AA 112-270
-
Origin
- Human
-
Source
- Escherichia coli (E. coli)
- Application
- SDS-PAGE (SDS)
- Specificity
- Binds to human ST2.
- Cross-Reactivity
- Human
- Characteristics
- Human IL-33 (aa 112-270) is untagged. Amino acids C208 and C232 have been mutated to serine to protect IL-33 from oxidation.
- Purity
- >95 % (SDS-PAGE)
- Endotoxin Level
- <0.01EU/μg purified protein (LAL test, Lonza).
- Top Product
- Discover our top product IL33 Protein
-
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Comment
-
Activates human ST2-dependent NF-kappaB pathway.
- Restrictions
- For Research Use only
-
- Format
- Solid
- Concentration
- Lot specific
- Buffer
- Lyophilized. Contains PBS.
- Storage
- 4 °C,-20 °C
- Storage Comment
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 6 months after receipt when stored at -20°C. - Expiry Date
- 6 months
-
- Target
- IL-33 (IL33) (Interleukin 33 (IL33))
- Alternative Name
- IL-33 (IL33 Products)
- Synonyms
- IL33 Protein, C9orf26 Protein, DVS27 Protein, IL1F11 Protein, NF-HEV Protein, NFEHEV Protein, RP11-575C20.2 Protein, 9230117N10Rik Protein, Il-33 Protein, Il1f11 Protein, RGD1311155 Protein, interleukin 33 Protein, IL33 Protein, Il33 Protein
- Background
- Interleukin-33 (IL-33, HF-NEV, IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL-33 binds to and signals through ST2 (IL-1R1) and its stimulation recruits MYD88, IRAK, IRAK4 and TRAF6, followed by phosphorylation of ERK1 (MAPK3) / ERK2 (MAPK1), p38 (MAPK14) and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases and sepsis. IL-33 facilitates Treg expansion in vitro and in vivo. Recently, IL-33 has been involved in adipocyte differentiation. The biological activity of IL-33 at its receptor ST2 is rapidly terminated in the extracellular environment by its oxidation (formation of two disulfide bridges), resulting in an extensive conformational change that disrupts the ST2 binding site. Mutations at amino acids C208S/C232S protect IL-33 from oxidation and increase its activity.
- Molecular Weight
- ~17kDa
- UniProt
- Q2YEJ5
- Pathways
- Production of Molecular Mediator of Immune Response
-